BMO Capital initiated coverage of Certara (CERT) with a Market Perform rating and $9 price target BMO remains a big believer in the longer-run opportunities associated with modernizing the currently antiquated drug development process, but would like to see more evidence that these initiatives are gaining traction before getting more constructive on the stock, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERT:
- Certara’s Earnings Call: Mixed Sentiment Amid Growth
- Certara price target lowered to $12 from $13 at Baird
- Certara price target lowered to $14 from $16 at Barclays
- Certara’s Mixed Performance: Strong Profitability Amidst Service Booking Challenges Leads to Hold Rating
- Certara, Inc. Reports Strong Q3 2025 Results